bicalutamid kabi 150 mg potahované tablety por tbl flm 98x150mg - Suchergebnisse

Irland - Englisch - HPRA (Health Products Regulatory Authority)

bicalutamide 50mg film-coated tablets

fresenius kabi deutschland gmbh - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Irland - Englisch - HPRA (Health Products Regulatory Authority)

bicalutamide 50 mg film-coated tablets

accord healthcare ireland ltd. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bicalutamide tablet, film coated

northstar rxllc - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies ( 14.2)]. bicalutamide is contraindicated in: hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. women bicalutamide has no indication for women, and should not be used in this population. pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman. [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for us